The global burden of gout is escalating, with prevalence expected to climb by more than 70% by 2050, according to projections reported by rheum-live.com. In the United States alone, over 9 million adults have been diagnosed with the disease, while an estimated 44 million people have elevated uric acid levels that could lead to gout, according to data from the Journal of the American Medical Association and the National Institutes of Health. This growing patient population faces a treatment landscape that is often limited by tolerability challenges, creating an urgent need for better options.
Current standard-of-care treatments, primarily oral xanthine oxidase inhibitors, can cause severe gastrointestinal issues, kidney toxicity, and cardiovascular risks. Approximately 3% to 5% of patients cannot tolerate these drugs, and many experience initial flare-ups that discourage adherence. These limitations have left a significant gap for patients who need effective, long-term uric acid management.
XORTX Therapeutics Inc. (NASDAQ: XRTX), a late-stage clinical pharmaceutical company, is developing XORLO™, a proprietary formulation of oxypurinol designed to overcome these hurdles. XORLO uses a liposomal delivery system to enhance oral absorption, allowing for lower total daily doses and reduced side effects. According to the company, this approach minimizes the toxic-level exposure and severe gastrointestinal issues associated with high-dose traditional therapies. The drug aims to provide effective uric acid suppression with better tolerability, potentially improving patient adherence.
The company recently announced the launch of drug material and tablet manufacturing to support a planned two-part clinical study of XORLO, known as XRX-OXY-102. This study is being advanced based on positive prior clinical results and discussions with the FDA. Contract production of pure oxypurinol, the active ingredient in XORLO, has already begun using XORTX's proprietary synthetic pathway, and the company is working with its manufacturing partner to produce commercial drug batches. These steps are critical for generating the clinical supply needed for regulatory submission.
XORTX is also working toward a new drug application submission to the FDA for XORLO. The company has prepared a new Investigational New Drug application for submission in the fourth quarter of 2026, which outlines its clinical development plan. If the two-part clinical trial is completed successfully, XORTX intends to request a pre-NDA meeting and prepare an NDA submission while engaging in pre-commercialization activities. The company is targeting an NDA submission in about one year and estimates a market opportunity of $700 million annually for XORLO.
"Our planned IND submission to the FDA next quarter is a defining step for the XRx-026 program," said Allen Davidoff, Co-CEO of XORTX. "It reflects the strength of our prior clinical results and moves us closer to potentially offering gout patients a differentiated treatment option."
For investors, the progress of XORLO represents a potential catalyst in a market with substantial unmet need. The gout treatment space has seen limited innovation, and a new option that addresses tolerability could capture significant share. XORTX's dual focus on gout and progressive kidney disease further broadens its potential impact. As the company advances manufacturing and regulatory milestones, its ability to execute on the NDA timeline will be closely watched. More information about XORTX can be found on Stocks.news, and the original announcement is available on www.newmediawire.com.
